Original Research
Published on 18 Aug 2022
Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer
in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
- 3,723 views
- 2 citations